Belharra Therapeutics, Inc. is a privately held drug discovery company whose novel photoaffinity-based chemoproteomics platform is disrupting the drug discovery paradigm. Guided by a diverse team of biotech trailblazers, Belharra’s proprietary noncovalent drug discovery engine is uniquely capable of identifying novel starting points for transformative medicines to address previously impossible-to-treat diseases and conditions.  The company’s next generation chemoproteomics platform enables Belharra scientists to identify small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type. Originating with Christopher G. Parker, Ph.D. and John Teijaro, Ph.D. at Scripps Research and pioneers in the field of chemical biology and serial biotech founders Benjamin Cravatt, Ph.D. at Scripps Research and Stuart Schreiber, Ph.D. at the Broad Institute of MIT and Harvard, the four co-founded Belharra Therapeutics in 2021 with a $50M Series A financing from Versant Ventures and incubation at Inception Therapeutics. Belharra is headquartered in the San Francisco Bay Area with its primary lab and offices in San Diego, California.